Orchestra BioMed Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.0%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$1.50next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
BACKBEAT Global Pivotal Trial Enrollment Completion QuarterlyTarget: Enrollment completion by the end of Q3 2026
Cash Runway QuarterlyTarget: Fund operations into Q4 2027
Virtue Trial Site Activation and Patient Enrollment QuarterlyTarget: Site activation and patient enrollment acceleration throughout 2026
Watch Items
- BACKBEAT Trial Late-Breaking Clinical Data PresentationTrigger: Q2 2027 presentation at major cardiology conferenceAction: Evaluate primary endpoints and prepare FDA marketing application submission
- Medtronic Strategic Collaboration MilestonesTrigger: FDA application submission for AVIM Therapy post-Q2 2027 dataAction: Coordinate regulatory submissions and prepare for commercial integration
Research as of 20 Jun 2026